ANNOUNCING VALENS AS A SILVER PARTNER FOR CANNABIS EUROPA LONDON
Cannabis Europa is excited to announce Valens as a Silver Partner for our London conference this June at the Southbank Centre.
Valens is a British-Columbia based company specialising in extraction, testing, formulation and product developmentof medical cannabis. With partnerships across the world and plans to process in Europe under EU GMP certification, achieving the highest quality is personal, and what makes Valens the “best in class”.
Cannabis Europa is the foremost arena to share knowledge and shape the future of medical cannabis in Europe, dedicated to creating a platform for European leadership in the global cannabis industry. Leaders gather for thought-provoking panel discussions that aim to solve uniquely European issues facing this nascent industry, welcoming Valens as a renowned leader in the Canadian market where cannabis is nationally legal for medical and adult use.
Lessons from Canada
Cannabis Europa brings together European entrepreneurs and leading operators in the medical cannabis industry to discuss the future of the industry, as well as medicine in general. On June 24th and 25th we will explore the technological and health innovations cannabis brings to the heath tech scene, as well as impacts of innovation on shaping product standardisation and some of the ways in which tech can empower patients. With more oil derivative products coming online in Canada this fall, the country has been hard at work developing a number of innovative offerings for medical and recreational patients. Valens specifically has had a heavy hand in working towards the elevation and standardization of cannabis testing, working alongside the world’s best scientific instrumentation companies, as well as providing extraction, formulation and white label services at scale for licensed producers across Canada.
Valens plans to enter the European market through extraction operations. Its subsidiary Valens Agritech in Canada is a purpose-built facility in compliance with European Union (EU) Good Manufacturing Practices (GMP) standards, ensuring the product from this facility can be exported anywhere in the world, including Europe, where cannabis is nationally legal for medical or adult usage purposes.
“We are in the second inning of the development of one of the largest industries in the world and the hard work we put in today will lay the framework around the world” said Everett Knight, Executive Vice President, Strategy & Investments. “It’s personal to me. I’ve seen the benefits of cannabis first hand and I have a responsibility to pass on the knowledge I have accumulated so that others can have access to cannabis around the globe.” Everett Knight, CFA, Executive Vice President, Strategy & Investments, Valens.
Cannabis Europa London will discuss the most important trends and challenges in the evolving European market, offering a meeting space for both European entrepreneurs and experienced global operators. Join the conversation now and book your ticket.